MRRS adds "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016" latest studies, published in December 2016. It is a professional and in-depth study.

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the five quarters.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Press Release

Deals in Pharmaceutical & Healthcare Industry Decreased in Q3 2016

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q3 2016. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

Number of M&A’s Decreased In Q3 2016

Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and deal values in Q3 2016 with 113 deals worth USD31.5 billion, compared to 273 deals worth USD75.1 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2016, compared to 135 deals worth USD96.1 billion in Q2 2016.

The central nervous system therapeutics market accounted for the majority of M&As with 145 deals worth USD66.6 billion between Q3 2015 and Q3 2016. Oncology therapeutics market followed in second place with 140 deals worth USD98.6 billion.

Partnerships Decreased In Q3 2016

Partnerships reported a marginal decrease in the number of deals and an increase in deal values with 192 deals worth USD4.5 billion in Q3 2016, compared to 197 deals worth USD3.3 billion in Q3 2015. On a quarter-on-quarter basis, the number of partnerships and their values decreased in Q3 2016, compared to 273 deals worth USD4.6 billion in Q2 2016.

Pharmaceutical and healthcare companies entered into 192 partnerships for Preclinical stage products, which accounted for 31% of the deals from Q3 2015 to Q3 2016. Products in Phase II stage stood second with 112 deals, which accounted for 18% of the deals.

Oncology therapeutics market recorded the highest value with USD11.1 billion deal value, USD1.8 billion milestone payments and USD981m upfront payments between Q3 2015 and Q3 2016, followed by the immunology market with USD10.1 billion in deal value, USD1.9 billion milestone payments and USD1.6 billion upfront payments.

Licensing Deals Repoted A Decline In Q3 2016

Licensing agreements reported a decrease in the number of deals and deal values in Q3 2016 with 138 deals worth USD10.2 billion in Q3 2016, as compared to 157 deals worth USD11.5 billion in Q3 2015. On a quarter-on-quarter basis, the number of licensing deals and their values decreased in Q3 2016, compared to 145 deals worth USD11.5 billion in Q2 2016.

Licensing agreements recorded a decrease in upfront payments and milestone payments in Q3 2016. A total of USD592.7m and USD5 billion were reported as upfront and milestone payments in Q3 2016, compared to USD707.5m and USD7.8 billion, respectively in Q3 2015. On a quarter-on-quarter basis, upfront payments and milestone payments decreased in Q3 2016, compared to USD1.1 billion and USD9.4 billion, respectively, in Q2 2016.

In licensing by phase, products in Preclinical stage recorded 175 deals, which accounted for 33% of the total deals between Q3 2015 and Q3 2016. In second place, products in Phase II accounted for 17% of the deals.

Venture Capital Investments Decreased In Q3 2016

The venture capital (VC) segment reported 174 deals worth USD2.1 billion in Q3 2016, as compared to 201 deals worth USD3.5 billion in Q3 2015. On a quarter-on-quarter basis, the number of VC deals and their values decreased in Q3 2016, compared to 197 deals worth USD2.4 billion in Q2 2016.

Orbimed Advisors, LLC topped the list of venture financing firms by participating in 33 transactions worth USD1.5 billion in the last five quarters (Q3 2015 – Q3 2016).

Deals In North America Reported A Decrease In Q3 2016

North America recorded a decrease in the number of deals and deal values in Q3 2016. The region registered 613 deals worth USD55.9 billion in Q3 2016, compared to 704 deals worth USD74.2 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2016, when compared to 708 deals worth USD132.2 billion in Q2 2016.

Europe recorded a decrease in the number of deals and deal values in Q3 2016 with 255 deals worth USD29.3 billion, as compared to 355 deals worth USD68.7 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2016, when compared to 335 deals worth USD24.2 billion in Q2 2016.
...

Browse Complete Report with TOC @
[URL]http://www.marketresearchreportstore.com/shop/partnerships-licensing-investments-and-ma-deals-and-trends-in-pharmaceuticals-q3-2016[/URL]

Ask a sample or any question, please feel free to contact us:

Tel: +00-1-626-3463946 - U.S

Email: [email protected]

[URL]http://www.marketresearchreportstore.com/[/URL]


About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.